Abstract Details
|
Tahseen Mozaffar, MD, FAAN
(University of California Irvine)
PRESENTER |
Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amicus. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astellas Gene Therapy. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics. The institution of Dr. Mozaffar has received research support from NIH. The institution of Dr. Mozaffar has received research support from Muscular Dystrophy Association. The institution of Dr. Mozaffar has received research support from Sanofi. The institution of Dr. Mozaffar has received research support from Argenx. The institution of Dr. Mozaffar has received research support from Amicus Therapeutics. The institution of Dr. Mozaffar has received research support from Astellas Gene Therpay. The institution of Dr. Mozaffar has received research support from Cartesian. The institution of Dr. Mozaffar has received research support from Cabaletta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. |
| No disclosure on file | |
| No disclosure on file | |
| Phyllis C. Zee, MD, PhD (Northwestern Univ Medical School) | Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Apnimed. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CVS Caremark. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony. Dr. Zee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony Biosciences. Dr. Zee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals Inc.. Dr. Zee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apnimed. Dr. Zee has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for World Sleep Society. An immediate family member of Dr. Zee has stock in Teva. The institution of Dr. Zee has received research support from National Institutes of Health. The institution of Dr. Zee has received research support from Sleep Number. Dr. Zee has received intellectual property interests from a discovery or technology relating to health care. Dr. Zee has received intellectual property interests from a discovery or technology relating to health care. Dr. Zee has received publishing royalties from a publication relating to health care. |
| No disclosure on file | |
| No disclosure on file |